Related references
Note: Only part of the references are listed.Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis
Nathalie LeVasseur et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients
Naoki Hayashi et al.
CLINICAL BREAST CANCER (2019)
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
Simon Peter Gampenrieder et al.
BREAST CANCER RESEARCH (2019)
Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients
Annina Baumgartner et al.
BREAST (2018)
Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold
Yunju Kim et al.
CLINICAL BREAST CANCER (2018)
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
Naoko Matsuda et al.
JAMA ONCOLOGY (2018)
MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer
Joseph J. Weber et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2017)
Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer
Sandy C. Lee et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
Mette S. van Ramshorst et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
B. Schaefgen et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer
Birgit E. P. J. Vriens et al.
EUROPEAN JOURNAL OF CANCER (2016)
Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype
Takayo Fukuda et al.
SPRINGERPLUS (2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
Kristine R. Broglio et al.
JAMA ONCOLOGY (2016)
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
Michael L. Marinovich et al.
BMC CANCER (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Eun Sook Ko et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
M. L. Marinovich et al.
BRITISH JOURNAL OF CANCER (2013)
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer Translational Breast Cancer Research Consortium Trial 017
Jennifer F. De los Santos et al.
CANCER (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy
Michael L. Marinovich et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy-Results from ACRIN 6657/I-SPY TRIAL
Nola M. Hylton et al.
RADIOLOGY (2012)
Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients
Randal Croshaw et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Claudette E. Loo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF ONCOLOGY PRACTICE (2010)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Neoadjuvant chemotherapy for operable breast cancer
J. S. D. Mieog et al.
BRITISH JOURNAL OF SURGERY (2007)
Pathobiology of preoperative chemotherapy - Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18
ER Fisher et al.
CANCER (2002)
Share Paper
